Clariane (CLARI.PA) Shares Slide in a Calm Trading Day
In a market session that remained largely steady, Clariane’s shares closed down 0.24 % at 08:36 AM Central Europe on Friday 23 October. The stock is currently priced at approximately EUR 3.14 on the principal exchanges. With a circulating supply of 357.5 million shares, the company’s market capitalisation stands at about EUR 1.3 billion. Over the last 24 hours, roughly EUR 660.8 thousand of Clariane stock has changed hands.
Technical Snapshot
- Simple Moving Average (200 days): EUR 3.91
- 52‑Week High: EUR 4.55 (27 October 2025)
- 52‑Week Low: EUR 3.12 (8 October 2026)
Since the end of last month, Clariane shares have fallen 17.77 %. Despite this decline, the price remains within a relatively narrow band defined by the 52‑week range.
Contextual Performance
Clariane’s movement is part of a broader trend among its peers. The following table summarizes recent 24‑hour performance for several comparable listings:
| Stock | 24‑Hour Change | Current Price (EUR) | Market Capitalisation (EUR bn) | P/E Ratio |
|---|---|---|---|---|
| M6‑Metropole Television (MMT.PA) | –0.2 % | 10.24 | 1.4 | 12.81 |
| Opmobility (OPM.PA) | –0.89 % | 9.25 | 1.5 | 6.91 |
| Derichebourg (DBG.PA) | +0.84 % | 7.62 | 1.3 | 9.39 |
| Peugeot Invest (PEUG.PA) | –0.19 % | 52.7 | 1.3 | 5.58 |
| Electricité de Strasbourg (ELEC.PA) | +0.51 % | 155.4 | 1.2 | 8.67 |
Clariane’s modest decline aligns with the slight downward drift observed in several of its contemporaries, indicating a cautious sentiment among investors in the healthcare and related services sector.
Company Overview
Clariane is a subsidiary of Korian SE, a leading French health‑care provider that operates across France, Germany, Italy, and Belgium. Korian specialises in dependency‑care services, managing approximately 780 facilities as of October 2023, which include nursing homes, specialised clinics, assisted‑living units, and hospital‑and‑home‑care networks. The company, originally founded in 2001 and based in Paris, underwent a rebranding from Korian‑Medica S.A. to Korian in 2015. It went public on 24 November 2006 and is listed on NYSE Euronext Paris. Further information can be found on the company’s website at www.korian.com .
Outlook
Analysts will be watching for any earnings guidance or operational updates that could influence Clariane’s trajectory. The stock’s proximity to its 200‑day moving average suggests a potential support level, while the 52‑week low offers a floor for short‑term investors. As the sector continues to grapple with regulatory shifts and demographic changes, Clariane’s performance will likely remain a barometer for the broader European health‑care market.
